Cardinal Health (CAH) has seen notable market gains and widespread bullish sentiment. The company has made multiple strategic portfolio additions, including the acquisition of
Integrated Oncology Network. However, concerns remain due to issues of negative equity. Despite market underperformance at times, analysts from TD Cowen and Evercore ISI have upgraded the stock to '
Buy' and '
Outperform' respectively, while Bank of America also sees the stock as a strong value. Quarterly earnings have consistently beaten estimates leading CAH to raise their FY 2025 outlook. They have also seen an increase in demand for medical supplies, shown resilient growth despite market shifts, and strategic acquisitions seem to have paid off. The company is expanding its medical product distribution network, with a new center opening in Massachusetts.
Citigroup increased their price target for CAH to $129.00. CAH's dividend value also remains affirmed at $0.5056, appealing to investor security. They've also initiated partnerships such as the one with GI Alliance and expanded their businesses in the gastroenterology and diabetes sectors via two deals worth $3.9 billion.
Cardinal Health CAH News Analytics from Mon, 22 Apr 2024 07:00:00 GMT to Sat, 11 Jan 2025 20:58:29 GMT -
Rating 7
- Innovation 6
- Information 8
- Rumor 2
